IL6 and COVID-19: Recently, two patients with ARDS mediated by COVID-19 were treated with ex vivo expanded allogeneic Tregs, resulting in symptom improvement, rapid decrease in inflammatory markers (IL-6, IL-12, TNF-α, IFN-γ) and no adverse effects related to the treatment [237].